GSDMA and Crohn disease: In CD4+ naïve/central‐memory T cells (Figure 2C), increased GSDMA expression was associated with reduced risk for Crohn's disease (OR = 0.82, 95% CI 0.72–0.93), rheumatoid arthritis (OR = 0.91, 95% CI 0.87–0.96), and UC (OR = 0.68, 95% CI 0.60–0.77), but increased risk for PSC (OR = 1.21, 95% CI 1.06–1.37); the pooled estimate in this lineage was not different from 1.0 (pooled OR = 0.92, 95% CI 0.80–1.04; I2 = 85%).